[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"advanced-hodgkin-lymphoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:advanced-hodgkin-lymphoma":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,43,70],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100573345","phase-2-personalized-reduction-of-chemotherapy-intensity-through-ctdna-evaluation-for-the-treatment-of-patients-with-advanced-hodgkin-lymphoma-100573345",false,"NCT06745076","Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma","A Multicenter Study PRECISE-HL: Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation in Advanced Hodgkin Lymphoma","Inclusion Criteria:\n\n* Classical Hodgkin lymphoma without prior systemic therapy, stage 3 or 4. Corticosteroids for symptom relief are allowed\n* Measurable disease per Lugano criteria\n* Patients must be appropriate candidates for 6 cycles of combination chemotherapy including an anthracycline\n* No evidence of active central nervous system lymphoma\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-2\n* Absolute neutrophil count (ANC) ≥ 500\u002Fmm\\^3. Growth factor and\u002For transfusion support is permissible to stabilize participant prior to study treatment if needed. There is no lower limit to cytopenias if related to bone marrow involvement or underlying Hodgkin lymphoma\n* Platelets ≥ 50,000\u002Fmm\\^3 (without transfusion or growth factor support). Growth factor and\u002For transfusion support is permissible to stabilize participant prior to study treatment if needed. There is no lower limit to cytopenias if related to bone marrow involvement or underlying Hodgkin lymphoma\n* Hemoglobin ≥ 8 g\u002FdL. Growth factor and\u002For transfusion support is permissible to stabilize participant prior to study treatment if needed. There is no lower limit to cytopenias if related to bone marrow involvement or underlying Hodgkin lymphoma\n* Serum creatinine \\\u003C 1.5 x upper limits of normal (ULN) or creatinine clearance greater than 30\u002Fml per minute by Cockcroft Gault formula\n* Total bilirubin ≤ 1.5 times upper limit of normal OR direct bilirubin ≤ ULN for participants with total bilirubin levels \\> 1.5 × ULN). Patients with Gilbert Syndrome and direct bilirubin \\\u003C 1.5 x ULN or confirmatory UGT1A1 testing are allowed to enroll\n* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 times upper limit of normal (≤ 5 × ULN for participants with liver involvement)\n* Patients must be age 18 or older\n* All patients must be informed of the investigational nature of this study and have given written consent in accordance with institutional and federal guidelines\n* Patients must be anticipated to complete all planned study therapy\n* Male patients must agree to use an adequate method of barrier contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy\n* Female patients of childbearing potential must have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required\n* Female patients of childbearing potential must be willing to use 2 methods of birth control or be surgically sterile or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study medication. Subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for \\> 1 year\n\nExclusion Criteria:\n\n* Patients known positive for HIV or infectious hepatitis type B or C with a detectable viral load may not participate. Hepatitis B\u002FC, and HIV testing are not required at screening unless mandated by local health authority.\n\n  * Patients living with HIV, on anti-viral treatment and undetectable viral load are allowed\n  * Patients with positive hepatitis (hep) B core antibody are allowed on study with an undetectable viral load and appropriate prophylaxis\n  * Patients with positive hepatitis C antibody are allowed with undetectable viral load\n* Pregnant or nursing women. Men or women of reproductive potential may not participate unless they have agreed to use an effective contraceptive method\n* Patients with other prior malignancies except for adequately treated basal cell carcinoma, squamous cell carcinoma of the skin, breast or cervical cancer in situ, or other cancer from which the patient has been disease-free for 2 years or greater, unless approved by the principal investigator\n* Patients who have other medical conditions that would contraindicate treatment with aggressive chemotherapy (including active infection, uncontrolled hypertension, congestive heart failure, unstable angina pectoris, or myocardial infarction within the past 6 months, uncontrolled arrhythmia, severe pulmonary disease or requirement of supplemental oxygen)\n* Active ischemic heart disease (eg. myocardial infarction within 6 months) or congestive heart failure (eg. left ventricular ejection fraction \\\u003C 50%)\n* Concurrent use of other anti-cancer agents or experimental treatments\n* Known current or prior autoimmune disease with the exception of vitiligo. Patients with a history of autoimmune thyroid disease on a stable dose of thyroid hormone are also allowed\n* Active or prior history of pneumonitis\u002Finterstitial lung disease that required corticosteroids\n* Current use of supplemental oxygen\n* Is known to have received a live vaccine or live-attenuated vaccine within 30 days prior to the first dose of trial treatment. Other non-live or live-attenuated vaccines (eg. COVID, Influenza) are allowed","ALL","18 Years",{"count":19,"type":20},125,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This phase II trial tests how well personalized reduction of chemotherapy (nivolumab, doxorubicin, vinblastine and dacarbazine) based on circulating tumor deoxyribonucleic acid (ctDNA) evaluation works for treating patients with Hodgkin lymphoma that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Chemotherapy drugs, such as nivolumab, doxorubicin, vinblastine and dacarbazine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Many types of tumors tend to lose cells or release different types of cellular products including their DNA, which is referred to as ctDNA, into the bloodstream before changes can be seen on scans. Health care providers can measure the level of ctDNA in blood or other bodily fluids and, based on the result, assign patients to a reduced number of chemotherapy treatments or the standard number of chemotherapy treatments. Using ctDNA to assign a personalized reduction of chemotherapy may be effective in treating patients with advanced Hodgkin lymphoma.",[26,27,28,29],"Advanced Hodgkin Lymphoma","Classic Hodgkin Lymphoma","Lugano Classification Stage III Hodgkin Lymphoma AJCC v8","Lugano Classification Stage IV Hodgkin Lymphoma AJCC v8","RECRUITING","2026-03-04",{"date":33,"type":34},"2026-03-05","ACTUAL",{"date":36,"type":34},"2025-03-06",{"date":38,"type":20},"2033-01-03",{"name":40,"class":41},"University of Washington","OTHER",5,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":54,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":69},"100593113","phase-2-brecadd-therapy-in-stage-2-b-iv-hodgkin-lymphoma-100593113","NCT07002216","BrECADD Therapy in Stage 2 B-IV Hodgkin Lymphoma","A Phase 2 Trial of Abbreviated Brentuximab Vedotin, Etoposide, Cyclophosphamide, Adriamycin, Dacarbazine, and Dexamethasone (BrECADD) Therapy in Stage 2 B-IV Hodgkin Lymphoma","BrECADD","Inclusion Criteria:\n\n1. Men and women ≥18 years of age and ≤60 years of age on the day of signing the informed consent form (or the legal age of consent in the jurisdiction in which the study is taking place).\n2. Patients must have histologic confirmation of classical Hodgkin Lymphoma (cHL) defined by the World Health Organization (WHO) classification.\n3. Baseline Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) Computed Tomography (CT) must demonstrate Fluorodeoxyglucose (FDG) avid lesions compatible with computed tomography (CT)-defined anatomical tumor sites. Patients should have at least 1 measurable site of disease per Lugano classification in Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography (FDG-PET\u002FCT) or CT scans.\n4. Patients must have a clinical stage consistent with:\n\n   a. Stage 2 B cHL with one or both of the following risk factors: i. Large mediastinal mass (≥1\u002F3 of the maximum transverse thoracic diameter) ii. Extranodal disease b. Stage III or Stage IV cHL based on Lugano criteria based on FDG-PET\u002FCT.\n5. Eastern Cooperative Oncology Group (ECOG) performance score (PS)≤ 2, except due to lymphoma involvement.\n6. Life expectancy ≥3 months.\n7. Women should avoid becoming pregnant for the full duration of chemotherapy and for up to 6 months after ending treatment. Therefore, women of childbearing potential must use highly effective contraceptive measures during treatment and for up to 6 months after stopping treatment. It is currently unknown whether brentuximab vedotin may reduce the effectiveness of hormonal contraceptives, and therefore, women using hormonal contraceptives should add a barrier method. Pregnancy testing is recommended for women of reproductive potential prior to initiating therapy.\n\n   Agreement to use contraception during study participation.\n   1. Female patients of childbearing potential must use highly effective methods of contraception.\n   2. Patients using hormonal contraceptives (eg, birth control pills or devices) must use a barrier method of contraception (eg, condoms) as well.\n   3. A woman is considered of childbearing potential, ie, fertile, following menarche and until becoming postmenopausal, unless permanently sterile. Permanent sterilization methods include hysterectomy, bilateral salpingectomy, and bilateral oophorectomy.\n   4. A post-menopausal state is defined as no menses for 12 months without an alternative medical cause.\n8. Male patients with a female partner of childbearing potential are eligible if they abstain from sexual intercourse, are vasectomized, or if they agree to the use of barrier contraception with other methods described above during the study treatment period and for 120 days after the last dose of brentuximab vedotin.\n9. Patients must have normal organ and marrow function as defined below:\n\n   1. Absolute neutrophil count (ANC) \\>1,000 cells\u002Fmm3 independent of growth factor support within 7 days of study entry (≥750 cells\u002Fmm3 if lymphoma involvement of the bone marrow or spleen).\n   2. Platelets ≥75,000 platelets\u002Fmm3 independent of transfusion support within 7 days of study entry (≥50,000 platelets\u002Fmm3 independent of transfusion support within 7 days of study entry if lymphoma involvement of the bone marrow or spleen).\n   3. Hemoglobin \\>9 g\u002FdL or \\>8 g\u002FdL in case of bone marrow involvement by lymphoma independent of transfusion support within 7 days of study entry.\n   4. Serum total bilirubin ≤2x upper limit of normal (ULN; except patients with Gilberts syndrome).\n   5. Aspartate aminotransferase (AST; serum glutamic-oxaloacetic transaminase) and alanine transaminase (ALT; serum glutamic-pyruvic transaminase) ≤2.5x institutional ULN (≤3x institutional ULN if lymphoma involvement of the liver).\n   6. Creatinine within normal institutional limits or creatinine clearance ≥40 mL\u002Fmin (as estimated by the Cockcroft-Gault equation or alternative formula according to institutional guidelines) for patients with creatinine levels above institutional normal.\n10. Able to provide written informed consent and can understand and agree to comply with the requirements of the study and the schedule of assessments (SoA).\n\nExclusion Criteria:\n\n1. Stage I or Stage IIA (IIA) HL.\n2. Nodular lymphocyte-predominant HL.\n3. Prior systemic lymphoma therapy including prior treatment with brentuximab vedotin.\n\n   Note: Patients with prior treatment for indolent lymphoma are still eligible for participation as long as they did not receive anthracycline-based therapy.\n4. Any uncontrolled or clinically significant cardiovascular disease including the following:\n\n   1. Myocardial infarction within 6 months before screening;\n   2. Unstable angina within 3 months before screening;\n   3. New York Heart Association class III or IV congestive heart failure;\n   4. History of clinically significant arrhythmias (eg, sustained ventricular tachycardia, ventricular fibrillation, torsades de pointes).\n   5. Uncontrolled hypertension as indicated by ≥2 consecutive blood pressure measurements showing systolic blood pressure \\>170 mm Hg and\u002For diastolic blood pressure \\>105 mm Hg at screening.\n5. Active and\u002For ongoing autoimmune anemia and\u002For autoimmune thrombocytopenia (eg, idiopathic thrombocytopenia purpura).\n6. Uncontrolled concurrent illness, such as liver cirrhosis, diabetes, autoimmune disorder requiring immunosuppression or long-term corticosteroids (\\>10 mg daily prednisone equivalent), or any other serious medical condition, laboratory abnormality, or psychiatric illness which would compromise ability to comply with study procedures.\n7. Severe or debilitating pulmonary disease.\n8. Peripheral neuropathy ≥Grade 2.\n9. Concurrent malignancy requiring active therapy.\n10. Prior malignancy within the past 3 years, except for curatively treated basal or squamous cell skin cancer, non-muscle-invasive bladder cancer, carcinoma in situ of the cervix or breast, or localized Gleason score 6 prostate cancer.\n11. Active fungal, bacterial and\u002For viral infection requiring systemic therapy.\n12. Breastfeeding or pregnant women.\n13. Known active infection with human immunodeficiency virus (HIV), or serologic status reflecting active hepatitis B or C infection as follows:\n\n    1. Patients with positive HIV test and undetectable viral load will be eligible for this study.\n    2. Presence of hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb): Patients with presence of HBcAb, but absence of HBsAg, are eligible if hepatitis B virus (HBV) DNA is undetectable (\\\u003C20 IU), and if they are willing to undergo monitoring every 4 weeks for HBV reactivation.\n    3. Presence of hepatitis C virus (HCV) antibody: Patients with presence of HCV antibody are eligible if HCV ribonucleic acid (RNA) is undetectable.\n14. Patients with impaired decision-making capacity.\n15. Underlying medical conditions that, in the Investigator's opinion, will render the administration of study drug hazardous or obscure the interpretation of toxicity or AEs.\n16. Patients undergoing major surgery ≤4 weeks prior to receiving their first dose of BrECADD. Major surgery is defined as open-heart, reconstructive, transplant, removal of a brain tumor, or a damaged kidney surgery.\n17. Vaccination or requirement for vaccination with a live vaccine within 28 days prior to the first dose of study drug or at any time during planned study treatment.\n18. Hypersensitivity to brentuximab vedotin, any components of the BrECADD regimen, or any of the other ingredients of the applicable study medications.\n19. Concurrent participation in another therapeutic clinical trial.","60 Years",{"count":53,"type":20},48,[23],"The purpose of this study is to further assess the efficacy and tolerability of a regimen of Brentuximab Vedotin, Etoposide, Cyclophosphamide, Doxorubicin, Dacarbazine, and Dexamethasone (BrECADD) in patients with Stage 2 B-IV Hodgkin Lymphoma (HL) with an exploratory objective to assess the clinical utility of Circulating tumor DNA (ctDNA) as a biomarker for minimal residual disease (MRD) and depth of treatment response.",[57,26],"Hodgkin Lymphoma",[59],"Stage 2 B-IV Hodgkin Lymphoma","2025-10-30",{"date":62,"type":34},"2025-11-03",{"date":64,"type":34},"2025-07-15",{"date":66,"type":20},"2030-07-15",{"name":68,"class":41},"University of Miami",1,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":51,"enrollmentInfo":78,"targetDuration":4,"studyType":21,"phases":80,"briefSummary":81,"conditions":82,"keywords":84,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":69},"100609015","phase-2-pet-adapted-first-line-therapy-with-nivolumab-for-advanced-hodgkin-lymphoma-100609015","NCT07209059","PET-Adapted First-Line Therapy With Nivolumab for Advanced Hodgkin Lymphoma","A Single-Center Pilot Study Evaluating the Efficacy and Safety of First-Line Immunochemotherapy With Nivolumab Guided by Interim PET for Stratification and Hazard Minimization in Patients With Advanced Classical Hodgkin Lymphoma (FINISH-HL)","FINISH-HL","Inclusion Criteria:\n\n* Signed written informed consent prior to any study-specific procedures\n* Histologically confirmed classical Hodgkin lymphoma (cHL)\n* Newly diagnosed disease, Ann Arbor stage IIB (bulky), III, or IV\n* At least one measurable lesion ≥15 mm in the longest diameter (by CT)\n* Age between 18 and 60 years (inclusive)\n* ECOG performance status 0-2\n* PET-CT performed at baseline\n* No prior chemotherapy, radiotherapy, or immunotherapy for lymphoma\n* Adequate organ function, including:\n* Serum creatinine ≤ 0.2 mmol\u002FL\n* Absence of severe cardiac, pulmonary, hepatic, or renal dysfunction\n* Ability to comply with the study protocol and scheduled visits\n\nExclusion Criteria:\n\n* Active hepatitis B or C infection\n* Positive test for HIV\n* Pregnancy or breastfeeding\n* Prior or active autoimmune disease requiring systemic therapy\n* Vaccination with a live vaccine within 30 days prior to first nivolumab dose\n* History of non-infectious pneumonitis requiring corticosteroids\n* Prior malignancy (except for adequately treated basal cell carcinoma or cervical carcinoma in situ)\n* Congestive heart failure, unstable angina, recent myocardial infarction, or severe cardiac arrhythmias\n* Severe renal impairment (serum creatinine \\> 0.2 mmol\u002FL), unless lymphoma-related\n* Severe hepatic dysfunction, unless directly related to lymphoma\n* Severe pneumonia with respiratory failure or hypoxemia not corrected within 2-3 days\n* Sepsis or hemodynamic instability\n* Life-threatening bleeding events (e.g., gastrointestinal or cerebral hemorrhage)\n* Cachexia (total serum protein \\\u003C 35 g\u002FL), unless due to lymphoma-related liver damage\n* Decompensated diabetes mellitus\n* Any somatic or psychiatric condition that, in the investigator's judgment, precludes informed consent or study participation",{"count":79,"type":20},30,[23],"This is a single-center, open-label, phase 2 pilot study evaluating the efficacy and safety of a response-adapted first-line treatment strategy for patients with classical Hodgkin lymphoma (cHL) and unfavorable prognostic factors. The FINISH protocol (First-line Immuno-chemotherapy Navigated by Interim PET for Stratification and Hazard minimization In Hodgkin lymphoma) integrates nivolumab into induction therapy and tailors subsequent treatment based on interim PET-CT response. The study also includes exploratory monitoring of circulating tumor DNA (ctDNA) to investigate its role in early response assessment and residual disease detection.",[57,83,26],"Hodgkin Disease",[85,83,86,87,88,89,90,91,92,93,94,95,96],"Classical Hodgkin Lymphoma","Nivolumab","Immunotherapy","First-line treatment","PET-adapted therapy","Checkpoint inhibitors","ctDNA","Response-adapted treatment","EACOPD","AVD","PD-1 blockade","Circulating tumor DNA","2025-09-29",{"date":99,"type":34},"2025-10-06",{"date":101,"type":34},"2025-07-29",{"date":103,"type":20},"2028-12",{"name":105,"class":106},"National Research Center for Hematology, Russia","NETWORK"]